Wednesday, April 01, 2020 3:27:51 PM
Recent CTXR News
- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma • PR Newswire (US) • 04/11/2024 12:30:00 PM
- Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference • PR Newswire (US) • 04/04/2024 12:30:00 PM
- Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 03/18/2024 12:30:00 PM
- Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program • PR Newswire (US) • 03/07/2024 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/04/2024 05:15:18 AM
- Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration • PR Newswire (US) • 02/26/2024 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:23:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2024 09:18:59 PM
- Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences • PR Newswire (US) • 02/23/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 01:45:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:40:26 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 02/14/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:18:38 PM
- Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 02/14/2024 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2024 09:08:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2024 09:05:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:05:27 PM
- Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors • PR Newswire (US) • 01/23/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:05:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:04:14 PM
- Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters • PR Newswire (US) • 01/02/2024 01:31:00 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 01/02/2024 01:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/29/2023 09:05:44 PM
- Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 • PR Newswire (US) • 11/09/2023 01:30:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM